Drug Trial Radar · NCT00519675
Alitretinoin in the Treatment of Chronic Hand Eczema
Last checked: Nov 20, 2026Latest source record: May 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Planned (sponsor's estimate)
Start
May 2007
Primary completion
Not stated
Sponsor
- Lead sponsor
- Basilea PharmaceuticaIndustry
- Sponsor type
- Industry
- First posted
- Aug 23, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to investigate the safety and efficacy of alitretinoin in chronic hand eczema that is refractory to topical corticosteroids.
Conditions
- Eczema
Interventions
alitretinoinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety assessments
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Paris, France
Site not named
Saint-Etienne, France
Site not named
Berlin, Germany
Site not named
Dresden, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.